Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling

Ngoc Tran, Ganessan Kichenadasse, Katherine Morel, Rebecca Ormsby, Lisa M. Butler, Maggie M. Centenera, Pam Sykes

    Research output: Contribution to journalMeeting Abstractpeer-review

    Abstract

    The anti-diabetic drug Metformin (MET) has been shown to reduce the incidence of prostate cancer, while the anti-epileptic drug Valproic Acid (VPA) has also been shown to have an anti-tumor effect. Here we aimed to determine if the combination of MET and VPA would induce at least an additive anti-tumour effect in prostate cancer due to their different mechanisms of action, and whether common mutations in prostate cancer (e.g. TP53 and AR genes) would affect the response.
    Original languageEnglish
    Article numberAbstract LB-233
    JournalCancer Research
    Volume76
    Issue number14 Suppl.
    DOIs
    Publication statusPublished - Jul 2016
    EventAACR 107th Annual Meeting 2016 -
    Duration: 16 Apr 2016 → …

    Keywords

    • androgen receptor signaling
    • metformin
    • personalized prostate cancer treatment
    • valproic acid
    • Combination of metformin and valproic acid

    Fingerprint Dive into the research topics of 'Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling'. Together they form a unique fingerprint.

    Cite this